Quercetin as an augmentation agent in Treatment Resistant Schizophrenia”

Not Applicable

Recruiting

• Conditions: schizophrenia; Mental Health - Schizophrenia

• Registration Number: ACTRN12617000207314
• Lead Sponsor: niversity of Western Australia School of Medicine and Pharmacology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-02-08
• Last Update Posted: 10 December 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Primary diagnosis of schizophrenia
Treatment resistant schizophrenia
Absence of centrally mediated side effects e.g. sedation, EPSE
Stable medications for 2 months

Exclusion Criteria

Allergy to Quercetin or Quercetain (Registered Trademark)
Pregnancy or lactation
ongoing alcohol and substance abuse, brain damage or severe comorbid medical conditions that is likely to affect the CNS
Failure to respond to antipsychotic treatment because of non-adherence to treatment or intolerable side effects
Presence of a serious medical condition as defined as a disease that is likely to require an unplanned hospital admission for treatment in the period of the trial.
Use of medications which are likely to interact significantly with quercetin including: Digoxin, Verapamil, Cyclosporin, Topotecan, Quinidine, Raitanovir, Methotrexate, Dabigatran, Rivaroxaban. The Principal Investigator will evaluate the potential for interactions between quercetin and medications in the participant’s regimen.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of participants with a reduction in PANSS of 20% or greater.[60 days of active treatment]

Secondary Outcome Measures

Name	Time	Method
Proportion of participants with a 25% or greater inprovement on NOSIE.[60 days of active treatment];Proportion of participants with 25% or greater increase in Functional health, as measured by change in scores on the Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form[60 days of active treatment];Proportion of participants with 25% or greater improvement on Self-assessment of side effects of medications as measured by the My Medicines & Me Questionnaire (M3Q)[60 days of active treatment]